| アイテムタイプ |
itemtype_ver1(1) |
| 公開日 |
2024-09-09 |
| タイトル |
|
|
タイトル |
Influence of renal function on the clinical efficacy of carboplatin plus pemetrexed in patients with non-small cell lung cancer |
|
言語 |
en |
| 著者 |
Komeda, Kazuki
Hase, Tetsunari
Hara, Toru
Kimura, Tomoki
Kojima, Eiji
Abe, Takashi
Horio, Yoshitsugu
Goto, Yasuhiro
Ushijima, Futoshi
Watanabe, Shohei
Yamada, Yuki
Shimokata, Tomoya
Oguri, Tetsuya
Yamamoto, Masashi
Yanagisawa, Kiyoshi
Ando, Masahiko
Kondo, Masashi
Hasegawa, Yoshinori
Ishii, Makoto
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利 |
|
|
権利情報Resource |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
権利情報 |
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International |
|
言語 |
en |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
pemetrexed |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
glomerular filtration rate |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
non-small cell lung cancer |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Pemetrexed, a structural antifolate agent that is eliminated via renal excretion, is commonly used to treat non-squamous non-small-cell lung cancer (NS-NSCLC). Although poor renal function is associated with a high incidence of toxicities, the association of high renal function with chemotherapy efficacy and toxicity remains unknown. We aimed to investigate the effect of renal function on the efficacy and toxicity of carboplatin-pemetrexed chemotherapy in patients with NS-NSCLC. We performed a post-hoc analysis of a prospective observational study of carboplatin-pemetrexed treatment in NS-NSCLC patients. Baseline renal function was calculated using the Japanese estimated glomerular filtration rate (eGFR) formula, and the patients were then divided into two groups based on the eGFR: high-eGFR (eGFR ≥ 80 mL/min/1.73 m^2, N = 162) and low-eGFR (eGFR < 80 mL/min/1.73 m^2, N = 176) groups. Although the response rates in the high- and low-eGFR groups were similar (22.2% vs 23.9%, P = 0.7205), the disease control rate was significantly lower in the high-eGFR group than in the low-eGFR group (75.9% vs 84.7%, P = 0.043). Progression-free survival (PFS) and overall survival (OS) in the high-eGFR group were significantly shorter than those in the low-eGFR group (adjusted hazard ratio for PFS and OS, 1.32 [95% CI, 1.04–1.69; P = 0.0245] and 1.49 [95% CI, 1.15–1.93, P = 0.0023], respectively). The incidence of hematological and non-hematological toxicities was lower in the high-eGFR group. In conclusion, a high-eGFR is associated with poor efficacy and mild toxicity of carboplatin-pemetrexed in patients with NSCLC. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Nagoya University Graduate School of Medicine, School of Medicine |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプresource |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| ID登録 |
|
|
ID登録 |
10.18999/nagjms.87.3.483 |
|
ID登録タイプ |
JaLC |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/873.html |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0027-7622 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2186-3326 |
| 書誌情報 |
en : Nagoya Journal of Medical Science
巻 87,
号 3,
p. 483-497,
発行日 2025-08
|
09_Komeda.pdf (1.1 MB)
.png)
